Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
0.752
-0.062 (-7.58%)
Nov 21, 2024, 11:44 AM EST - Market open
Seres Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Seres Therapeutics stock have an average target of 5.63, with a low estimate of 1.25 and a high estimate of 10. The average target predicts an increase of 648.37% from the current stock price of 0.75.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for MCRB stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 5 | 5 | 4 | 4 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,229.26% | Nov 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $1.25 | Strong Buy | Maintains | $1.25 | +66.16% | Nov 13, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Oct 24, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,229.26% | Sep 13, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,229.26% | Aug 14, 2024 |
Financial Forecast
Revenue This Year
4.52M
from 126.33M
Decreased by -96.42%
Revenue Next Year
14.28M
from 4.52M
Increased by 215.76%
EPS This Year
-0.96
from -0.89
EPS Next Year
-0.56
from -0.96
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 23.3M | 77.2M | 77.7M | ||
| Avg | 4.5M | 14.3M | 25.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -81.6% | 1,606.3% | 444.3% | ||
| Avg | -96.4% | 215.8% | 77.2% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.84 | -0.17 | -0.13 | ||
| Avg | -0.96 | -0.56 | -0.46 | ||
| Low | -1.04 | -0.80 | -0.83 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.